Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03472274
Title Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fundacion CRIS de Investigacion para Vencer el Cancer
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Cisplatin + Doxorubicin + Methotrexate + Vinblastine

Cisplatin + Gemcitabine

Cisplatin + Gemcitabine + Paclitaxel

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.